Thrombocytopenia can arise from various conditions, including myelodysplastic syndromes
(MDS) and bone marrow failure (BMF) syndromes. Meticulous assessment of the peripheral …

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell
disorders characterized by ineffective hematopoiesis with abnormal blood cell development …

Patients with myelodysplastic syndromes (MDS) frequently experience a significant
symptom burden, which reduces health-related quality of life (HRQoL). We aimed to identify …

Patient-reported outcomes (PROs) are relevant and valuable end points in the care of
patients with myelodysplastic syndromes (MDS). However, a consensus-based selection of …

An effective communication is an integral part of the patient-physician relationship. Lac of a
healthy patient-physician relationship leads to a lower level of patient satisfaction, scarce …

Current Treatment Options in Oncology not a clear standard of care. For those without
previous luspatercept exposure it can be considered particularly if there is an SF3B1 …

Background Patients need to be supported in combining treatment with daily life. However,
measurement of supportive care indicators related to treatment-related side effects is under …

Background Disease progression and poor prognosis in higher-risk (HR) myelodysplastic
syndrome (MDS) create an urgent need for interventions to improve the patient care …

The heterogeneous group of myelodysplastic syndromes (MDS) needs an individualized
and patient-tailored therapeutic approach. Consensus-based guidelines for diagnosis and …

Objectives In patients with myelodysplastic syndromes (MDS) with> 20 transfusions and
ferritin levels> 1000 μg/L, international guidelines recommend iron chelation therapy (ICT) …